IO Biotech, Inc. (IOBT)
Largest Insider Buys in Sector
IOBT Stock Price History Chart
IOBT Stock Performance
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Insider Activity of IO Biotech, Inc.
Over the last 12 months, insiders at IO Biotech, Inc. have bought $11.01M and sold $1.79M worth of IO Biotech, Inc. stock.
On average, over the past 5 years, insiders at IO Biotech, Inc. have bought $24.66M and sold $1.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Novo Holdings A/S (10 percent owner) — $90M. Vivo Capital IX, LLC (10 percent owner) — $18M. Burkavage Brian (Chief Accounting Officer) — $10,125.
The last purchase of 5,000 shares for transaction amount of $5,175 was made by Burkavage Brian (Chief Accounting Officer) on 2023‑11‑22.
List of Insider Buy and Sell Transactions, IO Biotech, Inc.
| 2024-05-10 | Sale | Novo Holdings A/S | 10 percent owner | 658,809 0.8518% | $1.22 | $802,495 | -15.33% | |
| 2024-02-09 | Sale | Novo Holdings A/S | 10 percent owner | 658,809 0.8023% | $1.50 | $988,411 | -7.36% | |
| 2023-11-22 | Burkavage Brian | Chief Accounting Officer | 5,000 0.0076% | $1.03 | $5,175 | +47.13% | ||
| 2023-11-21 | Burkavage Brian | Chief Accounting Officer | 5,000 0.0074% | $0.99 | $4,950 | +57.73% | ||
| 2023-08-09 | Novo Holdings A/S | 10 percent owner | 2.47M 9.534% | $2.02 | $5M | -17.22% | ||
| 2023-08-09 | Vivo Capital IX, LLC | 10 percent owner | 3.16M 11.4408% | $1.90 | $6M | -17.22% | ||
| 2023-03-17 | Sullivan Amy | Chief Financial Officer | 25,000 0.1017% | $2.32 | $58,018 | -8.59% | ||
| 2021-11-09 | Lundbeckfond Invest A/S | 10 percent owner | 2.14M 51.9475% | $14.00 | $30M | -62.27% | ||
| 2021-11-09 | Novo Holdings A/S | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | ||
| 2021-11-09 | Vivo Capital IX, LLC | 10 percent owner | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | ||
| 2021-11-09 | Nielsen Jack | director | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | ||
| 2021-11-09 | HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | ||
| 2021-11-09 | Andersson Claus A. | director | 75,000 1.8182% | $14.00 | $1.05M | -62.27% | ||
| 2021-11-09 | Malier Vanessa | director | 325,000 7.8787% | $14.00 | $4.55M | -62.27% |
Insider Historical Profitability
| Novo Holdings A/S | 10 percent owner | 4429449 8.6633% | $1.18 | 2 | 2 | <0.0001% |
| Vivo Capital IX, LLC | 10 percent owner | 3157894 4.7933% | $1.18 | 2 | 0 | <0.0001% |
| Burkavage Brian | Chief Accounting Officer | 11500 0.0175% | $1.18 | 2 | 0 | |
| Lundbeckfond Invest A/S | 10 percent owner | 6049452 9.1824% | $1.18 | 1 | 0 | <0.0001% |
| Nielsen Jack | director | 3015545 4.5773% | $1.18 | 1 | 0 | <0.0001% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2690545 4.084% | $1.18 | 1 | 0 | <0.0001% |
| Andersson Claus A. | director | 1791490 2.7193% | $1.18 | 1 | 0 | <0.0001% |
| Malier Vanessa | director | 958559 1.455% | $1.18 | 1 | 0 | <0.0001% |
| Sullivan Amy | Chief Financial Officer | 25000 0.0379% | $1.18 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Vivo Capital | $10.68M | 9.37 | 6.17M | 0% | +$0 | 0.94 | |
| Novo Holdings A/S | $8.8M | 7.72 | 5.09M | -11.46% | -$1.14M | 0.62 | |
| Samsara Biocapital Llc | $6.3M | 5.53 | 3.64M | 0% | +$0 | 0.98 | |
| PFM Health Sciences | $4.05M | 3.55 | 2.34M | 0% | +$0 | 0.11 | |
| Morgan Stanley | $3.8M | 3.34 | 2.2M | -3.7% | -$146,095.05 | <0.0001 | |
| Marshall Wace | $3.68M | 3.2 | 2.11M | 0% | +$0 | 0.01 | |
| Bank of America | $3.19M | 2.8 | 1.84M | 0% | +$0 | <0.0001 | |
| Armistice Capital Llc | $2.98M | 2.62 | 1.72M | -10.39% | -$346,000.00 | 0.04 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $1.5M | 1.31 | 864,197 | 0% | +$0 | 1.1 | |
| Logos Global Management Lp | $854,321.00 | 0.75 | 493,827 | 0% | +$0 | 0.09 | |
| Fidelity Investments | $550,550.00 | 0.48 | 314,600 | New | +$550,550.00 | <0.0001 | |
| Renaissance Technologies | $289,000.00 | 0.25 | 167,200 | +88.08% | +$135,339.11 | <0.0001 | |
| Stonepine Capital Management Llc | $270,169.00 | 0.24 | 156,167 | -90.63% | -$2.61M | 0.22 | |
| Bridgeway Capital Management | $218,090.00 | 0.19 | 124,623 | -14.17% | -$36,009.71 | <0.01 | |
| Citadel Advisors LLC | $102,589.00 | 0.09 | 58,622 | +13.02% | +$11,821.31 | <0.0001 | |
| Geode Capital Management | $58,287.00 | 0.05 | 33,307 | +161.64% | +$36,009.60 | <0.0001 | |
| Xtx Topco Ltd | $27,767.00 | 0.02 | 15,867 | New | +$27,767.00 | <0.01 |